Accuray vs NovoCure
ARAY and NVCR side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARAY and NVCR compare
NovoCure is the larger company, worth 4.5 times as much as Accuray ($1.3B against $291M).
NovoCure grew revenue faster over the last twelve months (12.9% versus −12.3% for Accuray).
Accuray keeps more of each dollar of sales as profit, with a net margin of −12.2% compared with −16.8% at NovoCure.
NovoCure scores higher on the StockData Score (9 against 2 for Accuray), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARAY | NVCR |
|---|---|---|
| Size and price | ||
| Market cap | $291M | $1.3B |
| Share price | $2.44 | $11.14 |
| Change, 1 year | −94.1% | −1.6% |
| Change, 5 years | −98.8% | −88.5% |
| Beta (5Y) | – | 1.23 |
| Employees | 809 | 1,605 |
| StockData Score | ||
| Total score | 2 | 9 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 0 | 3 (better) |
| Performance score | 1 | 1 |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.7× (better) | 1.8× |
| P/B | 7.0× | 3.7× (better) |
| FCF yield | −4.4% | −1.9% (better) |
| Fair value | – | $16.21 |
| Margin of safety | – | 31.3% |
| Growth | ||
| Revenue growth (TTM) | −12.3% | 12.9% (better) |
| Revenue growth, 5Y average | 0.28% | 5.8% (better) |
| Profitability | ||
| Gross margin | 27.7% | 77.0% (better) |
| Operating margin | −6.6% (better) | −17.2% |
| Net margin | −12.2% (better) | −16.8% |
| FCF margin | −3.2% (better) | −3.4% |
| Return on equity | −80.1% | −35.2% (better) |
| Return on invested capital | −13.0% (better) | −70.8% |
| Financial health | ||
| Debt / equity | 3.55 | 0.07 (better) |
| Interest coverage | −0.8× | – |
| Current ratio | 1.50 | 2.49 (better) |
| Altman Z-score | −0.39 | 0.25 (better) |
| Piotroski F-score | 1 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | −0.23% (better) | −0.28% |
| Shareholder yield | −0.23% (better) | −0.28% |
| Ownership | ||
| Held by institutions | 59.9% | 88.5% |
| Held by insiders | 28.7% | 3.0% |
| Insider net buying, 12 months | $134K (better) | −$3.4M |
| Short interest, % of float | 6.6% | 11.4% |
Go deeper
- ARAY stock overview
- ARAY income statement
- ARAY valuation and score
- NVCR stock overview
- NVCR income statement
- NVCR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.